ALEC

Alector, Inc. (NASDAQ:ALEC) is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in South San Francisco, California. The company went public in February 2019 and focuses on developing therapies for neurodegenerative diseases including Alzheimer's disease, frontotemporal dementia, Parkinson's disease, and amyotrophic lateral sclerosis. Alector has built its research around an innovative approach called <b>immuno-neurology</b>, which targets the immune system's role in brain health, particularly focusing on microglial cells that serve as the brain's immune cells. The company has established strategic partnerships with major pharmaceutical companies including GlaxoSmithKline and AbbVie to advance its pipeline of potential treatments.